A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
研究单位：[1]Hoffmann-La Roche[2]Peking Union Medical College Hospital,Beijing City,China,100032[3]Sichuan Cancer Hospital,Chengdu City,China,610041[4]Zhejiang Cancer Hospital[5]Zhejiang Cancer Hospital cancer department,Hangzhou City,China,310022[6]Harbin Medical University Tumor Hospital[7]Department of Surgery[8]Pharmacy,Harbin,China,150049[9]Taizhou Hospital of Zhejiang Province,Linhai,China,317000[10]Fudan University Shanghai Cancer Center[11]Medical Oncology,Shanghai City,China,201315[12]Cancer Hospital Affliated to Xinjiang Medical University,Urumqi City,China,830011
研究目的：
This is a phase III, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in patients with Stage IIIb or Stage IV non-small cell lung cancer (NSCLC) who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy or after anti-PD-1 as monotherapy).
